Zecuity, launched in September 2015, is a transdermal system that delivers a therapeutic dose via a single-use, battery-powered patch wrapped around the upper arm or thigh.
Participants were randomized to either hydromorphone 1mg (n=64) or prochlorperazine 10mg plus diphenhydramine 25mg (n=62).
Results found that all primary endpoints for non-inferiority of extended-release naltrexone group were met; retention in treatment (P=0.04), group proportion of total number of opioid-negative urine drug tests (P<0.001), days of heroin use (P<0.001) and days of other illicit opioids use (P<0.001).
The studies looked at the safety, tolerability, and efficacy of 4 dose regimens of subcutaneous fremanezumab vs. placebo over 16 weeks.
The case involved a 30-year-old female with a history of anxiety and migraine who presented with complaints of malaise, right upper quadrant pain, worsening jaundice, dark colored urine, and itching; these symptoms had been going on for a few weeks.
Researchers conducted a randomized, double-blind study involving patients using chronic opioids who were scheduled to undergo colonoscopy.
The efficacy of Lyrica CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.
In the changing legal environment, pediatric physicians must review their approach to screening for marijuana use and discussing the associated health consequences
With regards to treatment, all of the patients responded to CSF pressure-/volume-lowering therapies (ie, acetazolamide or spironolactone).
In a statement the FDA said that products on sites they identified during the operation may be counterfeit, contaminated, expired or otherwise unsafe.
At the pharmacy level, a greater emphasis will be placed on counseling to help patients understand the risks associated with opioid use based on the new Centers for Disease Control and Prevention (CDC) guidelines.
The researchers found that the mean daily numerical rating scale average pain scores varied from 4.5 to 4.8 for all groups in the 652 participants in KODIAC-04, and were 4.6 for each group of the 700 participants in KODIAC-05.
"the dangers associated with failing to treat an opioid use disorder can outweigh the risks of co-prescribing MAT and benzodiazepines," said FDA Commissioner Scott Gottlieb.
The researchers observed an increase in life expectancy at birth from 2000 to 2015, from 76.8 to 78.8 years.
The Intellis platform records and monitors patient activity 24/7, which can be accessed by physicians to track and make treatment adjustments as needed.
Results showed that new persistent opioid use, defined as continued opioid prescription fills between 90 and 180 days after the index surgical procedure, were 4.8% compared to 0.1% in the non-procedure control group.
Results demonstrated that at 12 weeks after the first dose of fremanezumab, the CM group had reductions of monthly headaches; -4.6 days for the monthly dose, -4.3 days for the quarterly dose and -2.5 for the placebo group (P<0.0001).
The study concluded that the cost of medical grade oxygen for the acute treatment of CH is not prohibitively expensive for patients or for insurance providers.
Among patients with serum vitamin D levels <20 ng/mL, the prevalence of NP was 5.8 times higher than in patients with vitamin D levels ≥30 ng/mL.
Results showed that at the end of the 12-week trial participants in the Aimovig 140mg group had a reduction of 7 MMDs and the 70mg group had a reduction of 5.4 days, while the placebo group had a reduction of 2.7 days (P<0.001).
The non-invasive SpringTMS device is placed at the back of the patient's head where a forced magnetic pulse is delivered to treat an acute attack or to prevent a future migraine onset.
In clinical trials, treatment with Durolane effectively relieved pain and restored function for up to six months in patients with knee osteoarthritis.
n the AAOMS White Paper, the Association urges prescribing ibuprofen over opioids as first-line therapy to manage acute and post-op pain.
The PRECISION-ABPM study included 444 patients (408 with osteoarthritis; 36 RA) who had evidence of, or were at increased risk for, coronary artery disease.